LEXINGTON, Mass. -- (BUSINESS WIRE) -- BioScale, Inc. a life science company that develops high-precision, sensitive protein analysis technology, today announced that data from its internal research program and collaborations with the National Cancer Institute (NCI) Antibody & Protein Purification Unit and the Frank McCormick laboratory at UCSF Helen Diller Family Comprehensive Cancer Center were accepted for presentation and publication in the proceedings of the 104th Annual Meeting of the American Association for Cancer Research (AACR). The Conference will be held at the Walter E. Washington Convention Center in Washington, DC from April 6 - April 10, 2012. Details of the four poster presentations focusing on signal transduction pathway analysis, tumor fingerprinting, rapid assay development and cell line screening of siRNA sequences for viability and pathway disruption are presented below.
Nanoparticle-based RNAi Therapy for the Delivery of Personalized siRNA Payloads to KRAS-driven Tumors
|Author:||Tina Yuan, PhD et al; UCSF Helen Diller Family Comprehensive Cancer Center|
|Session, Date:||Late-Breaking Research: Experimental and Molecular Therapeutics 1|
|Monday, April 8, Hall A-C, Poster Section 46, 1:00PM - 5:00PM|
Development of Applications for Acoustic Membrane Microparticle Assay Technology for Translational Medicine (No.3208)
|Author:||Paul K. Goldsmith, PhD et al; (retired) National Cancer Institute|
|Session, Date:||Molecular and Cellular Biology 45|
|Proteomics and Metabolomics Technology Advances|
|Tuesday, April 9, Hall A-C, Poster Section 35, 8:00AM - 12:00PM|
Novel discovery of P38 activation: Expression in A431 cells in in vitro and in vivo Models of Cancer Measured by a Novel Assay for p-P38 (No. 5170)
|Author:||Lee Anne Beausang et al, BioScale, Inc.|
|Session, Date:||Molecular and Cellular Biology 63|
|Cancer Cell Signaling and Emerging Technologies|
|Wednesday, April 10, Hall A-C, Poster Section 24, 8:00AM – 12:00 PM|
A Panel of in vitro Kinase Assays Developed Using a Novel Detection Technology to Predict and Monitor EGFR Inhibitor Efficacy (No.5527)
|Author:||W. Matthew Dickerson, PhD et al, BioScale, Inc.|
|Session, Date:||Experimental and Molecular Therapeutics 39|
|Drug Discovery Technologies|
|Wednesday, April 10, Hall A-C, Poster Section 38, 8:00AM – 12:00PM|
About BioScale, Inc.
BioScale is a life science company that develops, manufactures and promotes a proprietary protein analysis technology to accelerate the discovery, development and production of biological and pharmaceutical products. BioScale’s innovative ViBE® platform powered by its AMMP® (Acoustic Membrane Microparticle) technology enables highly-sensitive detection and quantitation of proteins in complex samples used in pre-clinical and clinical research, bioprocess, patient point-of-care and personalized medicine applications. BioScale is headquartered in Lexington, MA. For more information, visit www.bioscale.com.